1228690-56-9 Usage
Uses
Used in Pharmaceutical Industry:
1-(2,3-Difluorophenyl)ethanol is used as a key intermediate in the synthesis of pharmaceutical compounds. Its unique structure allows for the development of new drugs with improved properties, such as enhanced potency, selectivity, and reduced side effects.
Used in Agrochemical Industry:
In the agrochemical industry, 1-(2,3-Difluorophenyl)ethanol serves as a building block for the synthesis of various agrochemicals, including pesticides and herbicides. Its incorporation into these compounds can lead to improved effectiveness and selectivity, reducing the environmental impact of these chemicals.
Used in Specialty Chemicals Production:
1-(2,3-Difluorophenyl)ethanol is also utilized in the production of specialty chemicals, such as fragrances, dyes, and polymers. Its unique properties enable the creation of novel compounds with specific characteristics, catering to the diverse needs of various industries.
Safety Precautions:
It is important to handle 1-(2,3-Difluorophenyl)ethanol with caution, as it may be harmful if ingested or inhaled, and may cause skin and eye irritation upon contact. Proper safety measures, such as wearing protective gear and working in a well-ventilated area, should be taken to minimize potential risks.
Check Digit Verification of cas no
The CAS Registry Mumber 1228690-56-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,2,8,6,9 and 0 respectively; the second part has 2 digits, 5 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 1228690-56:
(9*1)+(8*2)+(7*2)+(6*8)+(5*6)+(4*9)+(3*0)+(2*5)+(1*6)=169
169 % 10 = 9
So 1228690-56-9 is a valid CAS Registry Number.
1228690-56-9Relevant academic research and scientific papers
ANTAGONISTS OF LYSOPHOSPHATIDIC ACID RECEPTORS
-
Page/Page column 26, (2010/06/22)
Described herein are compounds that are antagonists of lysophosphatidic receptor(s). Also described are pharmaceutical compositions and medicaments that include the compounds described herein, as well as methods of using such antagonists, alone and in combination with other compounds, for treating LPA-dependent or LPA-mediated conditions or diseases.
